title: Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers.
abstract: Salmon calcitonin (SCT) is a well-tolerated peptide drug with a wide therapeutic margin and is administered parenterally for long-term treatments of bone diseases. Its clinical usefulness would be enhanced by the development of an orally active formulation. In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier. Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion. SCT was reliably absorbed from the oral formulation, with an absolute bioavailability of 0.5-1.4%, depending on the dose. It induced a marked, dose-dependent drop in blood and urine C-terminal telopeptide of type I collagen (CTX), a sensitive and specific bone resorption marker, with the effects of 1200 microg exceeding those of 10 microg intravenously. It also decreased blood calcium and phosphate, and increased the circulating levels of parathyroid hormone (PTH) and, transiently, the urinary excretion of calcium. It was well-tolerated, with some subjects presenting mild and transient nausea, abdominal cramps, diarrheic stools, and headaches. This study shows that oral delivery of SCT is feasible with reproducible absorption and systemic biological efficacy. Such an oral formulation could facilitate the use of SCT in the treatment of osteoporosis and other bone diseases.
authors.affiliation: Division of Clinical Pharmacology, University Hospital of Lausanne CHUV, Switzerland.
authors.forename: Thierry
authors.initials: T
authors.lastname: Buclin
authors.forename: Monica
authors.initials: M
authors.lastname: Cosma Rochat
authors.forename: Peter
authors.initials: P
authors.lastname: Burckhardt
authors.forename: Moïse
authors.initials: M
authors.lastname: Azria
authors.forename: Martine
authors.initials: M
authors.lastname: Attinger
mesh_terms: D000328:Adult; D001682:Biological Availability; D002116:Calcitonin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood / Q000652:urine; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006207:Half-Life; D006801:Humans; D008297:Male
chemical_list: C028815:salmon calcitonin; D002116:Calcitonin; D002118:Calcium